Relapsed and Refractory Acute Myeloid Leukemia (AML) Treated with AS1411 and Cytarabine: A Randomized Phase II Trial.

被引：0
|
作者：
Stuart, Robert Kenneth [1 ]
Acton, Gary [2 ]
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
[2] Antisoma Res Ltd, London, England
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：676 / 676
页数：1
相关论文
共 50 条
  • [1] Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML)
    Stuart, R. K.
    Stockerl-Goldstein, K.
    Cooper, M.
    Devetten, M.
    Herzig, R.
    Medeiros, B.
    Schiller, G.
    Wei, A.
    Acton, G.
    Rizzieri, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] AS1411 IN COMBINATION WITH CYTARABINE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
    Stuart, K.
    Stockerl-Goldstein, K.
    Cooper, M.
    Devetten, M.
    Herzig, R.
    Medeiros, B.
    Schiller, G.
    Wei, A.
    Acton, G.
    Rizzieri, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 336 - 336
  • [3] Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Foster, Matthew
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Scibilia, Richard
    Blanchard, Laura
    Frank, Cassiopeia
    Gallagher, Sean
    Matson, Melissa
    Pepin, Katherine
    Vaught, Lori
    Vogler, Nancy
    Gojo, Ivana
    Luznik, Leo
    Serody, Jonathan S.
    BLOOD, 2017, 130
  • [4] High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.
    Powell, Bayard
    D'Agostino, Ralph, Jr.
    Levitan, Denise
    Ellis, Leslie Renee
    Lyerly, Susan
    Skiles, Megan
    Manuel, Megan
    Harrelson, Robin
    Kimbrough, Claire
    Hurd, David Duane
    BLOOD, 2008, 112 (11) : 676 - 676
  • [5] A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
    Short, Nicholas J.
    Kantarjian, Hagop
    Ravandi, Farhad
    Huang, Xuelin
    Xiao, Lianchun
    Garcia-Manero, Guillermo
    Plunkett, William
    Gandhi, Varsha
    Sasaki, Koji
    Pemmaraju, Naveen
    Daver, Naval G.
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Kadia, Tapan M.
    Wierda, William G.
    DiNardo, Courtney D.
    Brandt, Mark
    O'Brien, Susan M.
    Cortes, Jorge E.
    Jabbour, Elias
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 813 - 820
  • [6] Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Moore, Dominic
    McKinnon, Karen P.
    Wilkinson, Alec D.
    Mukhopadhyay, Rupkatha
    Mazziotta, Francesco
    Knaus, Hanna A.
    Foster, Matthew C.
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Webster, Jonathan A.
    Prince, Gabrielle T.
    DeZern, Amy E.
    Smith, B. Douglas
    Levis, Mark J.
    Montgomery, Nathan D.
    Luznik, Leo
    Serody, Jonathan S.
    Gojo, Ivana
    BLOOD CANCER DISCOVERY, 2021, 2 (06): : 616 - 629
  • [7] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
  • [8] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Naqvi, Kiran
    Ravandi, Farhad
    Kantarjian, Hagop
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Thomas, Deborah A.
    Koller, Charles Asa
    Konopleva, Marina
    Byrd, Anna
    Kwari, Monica
    Faderl, Stefan
    BLOOD, 2010, 116 (21) : 464 - 465
  • [9] MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
    Montesinos, Pau
    Beckermann, Benjamin M.
    Catalani, Olivier
    Esteve, Jordi
    Gamel, Katia
    Konopleva, Marina Y.
    Martinelli, Giovanni
    Monnet, Annabelle
    Papayannidis, Cristina
    Park, Aaron
    Recher, Christian
    Rodriguez-Veiga, Rebeca
    Roellig, Christoph
    Vey, Norbert
    Wei, Andrew H.
    Yoon, Sung-Soo
    Fenaux, Pierre
    FUTURE ONCOLOGY, 2020, 16 (13) : 807 - 815
  • [10] Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies
    Rubnitz, JE
    Razzouk, BI
    Srivastava, DK
    Pui, CH
    Ribeiro, RC
    Santana, VM
    LEUKEMIA RESEARCH, 2004, 28 (04) : 349 - 352
12345